| Heading: |
Charcot Marie Tooth Disease: Cannabis |
| Question ID: |
1792304 |
| UIN: |
44130 |
| House: |
Commons |
| Date tabled: |
2025-04-03 |
| Asking Member ID: |
5234 |
| Asking Member display name: |
Laurence Turner
|
| Asking Member handle: |
larry_turner
|
| Asking Member Twitter reference: |
@larry_turner
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of prescribing medical cannabis to treat Charcot-Marie-Tooth Syndrome. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-08 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) does not recommend the use of any cannabis-based medicines to manage chronic or neuropathic pain in adults and that cannabidiol (CBD) only be offered as part of a clinical trial.NICE recognises ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |